VALEANT PHARMACEUTICALS INTERNATIONAL (NY:VRX)
33.28
0.38 (1.13%)
| VALEANT PHARMACEUTICALS INTERNATIONAL (NY:VRX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $33.66 | 52 Week High | $34.44 | ||
| Open | $33.46 | 52 Week Low | $15.64 | ||
| Day High | $33.80 | P/E | N/A | ||
| Day Low | $33.09 | EPS | $-0.45 | ||
| Volume | 508,623 | ||||
| More VRX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| FNM | 2 | FRE | 2 |
| NRP | 2 | PG | 2 |
| WCRX | 2 | CHIC | 2 |
| ENDP | 1 | OTEX | 1 |
| BRCM | 1 | GSK | 1 |
| CPST | 1 | PPCO | 1 |
Entities who have mentioned VRX
- Matrix USA | View Related Stories »
- Citi | View Related Stories »
- Soleil Securities | View Related Stories »
- Wachovia | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Morgan Stanley | View Related Stories »
- JANA Partners LLC | View Related Stories »
- Barry Rosenstein | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- Credit Suisse | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- JPMorgan | View Related Stories »
- Bankruptcy | View Related Stories »
- Goldman Sachs | View Related Stories »
- Jefferies & Co | View Related Stories »
- Daniel Loeb | View Related Stories »
- Lehman Brothers | View Related Stories »
- Banc of America | View Related Stories »
- Lazard | View Related Stories »
- ThinkEquity | View Related Stories »
- Natixis Bleichroeder | View Related Stories »
- Wilbur Ross | View Related Stories »
- Cowen & Co | View Related Stories »
- Wedbush Morgan | View Related Stories »
View All Major News StreetInsider.com Major News for VRX
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharmaceuticals (VRX) Tops Q2 EPS by 7c; Guides Above
- Valeant Pharmaceuticals (VRX) Tops Q1 View By 14c; Raises Prior Guidance
View All ReportsStreetInsider.com Reports on VRX
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharma's (VRX) Coria Labs May Market Acanya Gel as Effective Treatment for Moderate to Severe Acne
- Valeant (VRX) to Acquire Major Australian Skincare Brands For $69M And Issue 162.5k Shares
- Valeant (VRX) Buys-Out Rights to All Current and Future Income and Milestone Obligations From Former Dow Stockholders
- Unusual 11 Mid-Day Movers 8/24: FNM, MERC, FRE, WCRX Higher; RPRX, TWI, NRP, VRX Lower
View All Press ReleasesCompany Press Releases on VRX
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
- Valeant Pharmaceuticals Reports Third Quarter Financial Results
- Valeant to Acquire Polish Products
- Valeant Pharmaceuticals to Announce 2009 Third Quarter Results on November 2, 2009
- New Study Assesses Skin Hydration and Epidermal Function of 2.5% and 5% Benzoyl Peroxide-Clindamycin Combinations
StreetInsider Reports on VRX by Category
View All BlogsBlogs on VRX
- 37 Breakout Stocks on Big Volume, November 16, 2009
- Valeant Pharmaceuticals International Q3 2009 Earnings Call Transcript
- Valeant: It Turns Out that Wrinkles Are Worth Quite a Lot
- Tupperware: Unlikely Market Leader
- Best Performing Mid and Small Cap Stocks Since 10/9/07 Peak
View All FilingsSEC Filings on VRX
- Form 4 VALEANT PHARMACEUTICALS For: Nov 18 Filed by: Healey Joseph Patrick
- Form 4 VALEANT PHARMACEUTICALS For: Nov 18 Filed by: HealthCor Hybrid Offshore GP, LLC
- Form 4 VALEANT PHARMACEUTICALS For: Nov 18 Filed by: CHAUDHURI BHASKAR
- Form 8-K VALEANT PHARMACEUTICALS For: Nov 04
- Form 4 STEFANO STEPHEN F. For: Nov 04
Comments on VRX
No comments are currently available.
